The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Timeframe: Baseline (Day of Exposure) to Day 29 post-dose
Part B, C, D, E, & G: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Timeframe: Baseline (Day of Exposure) to Day 57 post-dose
Part F: Pharmacokinetics (PK): Area Under the Concentration curve (AUC) of LY3971297
Timeframe: Baseline Up to Day 29 post-dose for Part F
Part F: PK: Maximum Observed Drug Concentration (Cmax) of LY3971297
Timeframe: Baseline Up to Day 29 post-dose for Part F
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or